Genomic Epidemiology of SARS-CoV-2 in Ukraine from May 2022 to March 2024 Reveals Omicron Variant Dynamics.

Publication date: Jul 17, 2025

In Ukraine, SARS-CoV-2 detection and national genomic surveillance have been complicated by full-scale war, limited resources, and varying levels of public health infrastructure impacted across the country. Following the Spring of 2022, only a paucity of data have been reported describing the prevalence and variant dynamics of SARS-CoV-2 in the country. Comparative whole genome analysis has overtaken diagnostics as the new gold standard for detecting and tracing emerging variants while showing utility to rapidly inform diagnostics, vaccine strategies, and health policy. Herein, we provide an updated report characterizing the dynamics and prevalence of SARS-CoV-2 in Ukraine from 1 May 2022 to 31 March 2024. The present study extends previous reports for disease incidence Waves 1-4 in Ukraine with the addition herein of Waves 5, 6, and 7, occurring from August to November 2022 (Wave 5), February to May 2023 (Wave 6), and October 2023 to January 2024 (Wave 7). During the study period, the national Case Fatality Rate (CFR) fluctuated between 0. 46% and 1. 74%, indicating a consistent yet modest rate when compared to the global average. The epidemiological dynamics of Variants of Concern (VOCs) in Ukraine reflected global patterns over this period, punctuated by the rise of the BA. 5 lineage and its subsequent replacement by the Omicron subvariants XBB and JN. 1. Our analysis of variant dispersal patterns revealed multiple potential spatiotemporal introductions into Ukraine from Europe, Asia, and North America. Our results highlight the importance of ongoing genomic surveillance to monitor variant dynamics and support global efforts to control and mitigate COVID-19 disease risks as new variants arise.

Open Access PDF

Concepts Keywords
Fatality COVID-19
February COVID-19 surveillance
Ukraine Genome, Viral
Vaccine genomic epidemiology
genomic surveillance
Genomics
Humans
Incidence
Molecular Epidemiology
Omicron
pandemic
Phylogeny
Prevalence
public health
SARS-CoV-2
SARS-CoV-2
SARS-CoV-2 introductions
Ukraine
variant dynamics
whole genome sequencing

Semantics

Type Source Name
disease IDO country
drug DRUGBANK Gold
disease MESH COVID-19
disease IDO pathogen
drug DRUGBANK Coenzyme M
disease MESH infection
disease IDO virulence
disease MESH emergency
disease IDO host
disease IDO quality
disease MESH AIDS
drug DRUGBANK Diethylstilbestrol
disease IDO assay
drug DRUGBANK Trestolone
disease IDO algorithm
drug DRUGBANK Hyaluronic acid
disease MESH death
disease MESH respiratory diseases
drug DRUGBANK Huperzine B
disease MESH Avian Influenza
disease MESH Influenza
disease IDO immunodeficiency
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH pneumonia
drug DRUGBANK Troleandomycin

Original Article

(Visited 1 times, 1 visits today)